 Dolutegravir is an HIV-1 integrase inhibitor which is marketed as a single tablet Tivicay and in a fixed dose combination tablet with abacavir and lamivudine Triumeq, referred to as TRI. For patients with swallowing difficulties, administration of whole tablets can be problematic and tablets are cut or crushed to ease administration. 